EV-304 / KEYNOTE-B15
The trial that could replace chemotherapy before bladder removal in fit patients with an ADC plus immunotherapy.
Topline December 2025: statistically significant improvements in EFS, OS, and pCR versus neoadjuvant chemotherapy; full data and regulatory filing expected in 2026. Together with EV-303 and EV-302, it would make EV + pembrolizumab the default across the bladder cancer continuum.
Pages like this
not linked directly; found by shared links- TrialEV-303 / KEYNOTE-905
Shares Enfortumab vedotin + pembrolizumab across the bladder cancer continuum, Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response, Enfortumab vedotin, Bladder & urothelial cancer.
- TrialEV-302 / KEYNOTE-A39
Shares Enfortumab vedotin + pembrolizumab across the bladder cancer continuum, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PersonShilpa Gupta
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PersonJae Lyun Lee
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- TechnologyADC payload neutralisers
- PairingADC + checkpoint inhibitor
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- CompanyAstellas
- CompanyGenerate:Biomedicines